Literature DB >> 21135191

Artemisone uptake in Plasmodium falciparum-infected erythrocytes.

Sophie Pooley1, Farrah A Fatih, Sanjeev Krishna, Michael Gerisch, Richard K Haynes, Ho-Ning Wong, Henry M Staines.   

Abstract

Artemisone is one of the most promising artemisinin derivatives in clinical trials. Previous studies with radiolabeled artemisinin and dihydroartemisinin have measured uptake in Plasmodium falciparum-infected erythrocytes. Uptake is much greater in infected than in uninfected erythrocytes, but the relative contributions of transport, binding, and metabolism to this process still await definition. In this study, we characterized mechanisms by which [(14)C]artemisone is taken up into uninfected and P. falciparum-infected human erythrocytes in vitro. Radiolabeled artemisone rapidly enters uninfected erythrocytes without much exceeding extracellular concentrations. Unlabeled artemisone does not compete in this process. Radiolabeled artemisone is concentrated greatly by a time- and temperature-dependent mechanism in infected erythrocytes. This uptake is abrogated by unlabeled artemisone. In addition, the uptake of artemisone into three subcellular fractions, and its distribution into these fractions, is examined as a function of parasite maturation. These data are relevant to an understanding of the mechanisms of action of this important class of drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21135191      PMCID: PMC3028811          DOI: 10.1128/AAC.01216-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Artemisone--a highly active antimalarial drug of the artemisinin class.

Authors:  Richard K Haynes; Burkhard Fugmann; Jörg Stetter; Karl Rieckmann; Hans-Dietrich Heilmann; Ho-Wai Chan; Man-Ki Cheung; Wai-Lun Lam; Ho-Ning Wong; Simon L Croft; Livia Vivas; Lauren Rattray; Lindsay Stewart; Wallace Peters; Brian L Robinson; Michael D Edstein; Barbara Kotecka; Dennis E Kyle; Bernhard Beckermann; Michael Gerisch; Martin Radtke; Gabriele Schmuck; Wolfram Steinke; Ute Wollborn; Karl Schmeer; Axel Römer
Journal:  Angew Chem Int Ed Engl       Date:  2006-03-20       Impact factor: 15.336

2.  Evidence of artemisinin-resistant malaria in western Cambodia.

Authors:  Harald Noedl; Youry Se; Kurt Schaecher; Bryan L Smith; Duong Socheat; Mark M Fukuda
Journal:  N Engl J Med       Date:  2008-12-08       Impact factor: 91.245

3.  Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism.

Authors:  Benoit Witkowski; Joel Lelièvre; María José López Barragán; Victor Laurent; Xin-zhuan Su; Antoine Berry; Françoise Benoit-Vical
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

4.  The Fe2+-mediated decomposition, PfATP6 binding, and antimalarial activities of artemisone and other artemisinins: the unlikelihood of C-centered radicals as bioactive intermediates.

Authors:  Richard K Haynes; Wing Chi Chan; Chung-Man Lung; Anne-Catrin Uhlemann; Ursula Eckstein; Donatella Taramelli; Silvia Parapini; Diego Monti; Sanjeev Krishna
Journal:  ChemMedChem       Date:  2007-10       Impact factor: 3.466

5.  Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation.

Authors:  Juan Wang; Liying Huang; Jian Li; Qiangwang Fan; Yicheng Long; Ying Li; Bing Zhou
Journal:  PLoS One       Date:  2010-03-08       Impact factor: 3.240

6.  Interaction of artemisinins with oxyhemoglobin Hb-FeII, Hb-FeII, carboxyHb-FeII, heme-FeII, and carboxyheme FeII: significance for mode of action and implications for therapy of cerebral malaria.

Authors:  Paolo Coghi; Nicoletta Basilico; Donatella Taramelli; Wing-Chi Chan; Richard K Haynes; Diego Monti
Journal:  ChemMedChem       Date:  2009-12       Impact factor: 3.466

7.  Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model.

Authors:  Ildiko R Dunay; Wing Chi Chan; Richard K Haynes; L David Sibley
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

8.  Artemisinin resistance in Plasmodium falciparum malaria.

Authors:  Arjen M Dondorp; François Nosten; Poravuth Yi; Debashish Das; Aung Phae Phyo; Joel Tarning; Khin Maung Lwin; Frederic Ariey; Warunee Hanpithakpong; Sue J Lee; Pascal Ringwald; Kamolrat Silamut; Mallika Imwong; Kesinee Chotivanich; Pharath Lim; Trent Herdman; Sen Sam An; Shunmay Yeung; Pratap Singhasivanon; Nicholas P J Day; Niklas Lindegardh; Duong Socheat; Nicholas J White
Journal:  N Engl J Med       Date:  2009-07-30       Impact factor: 91.245

9.  In vitro evaluation of the growth inhibitory activities of 15 drugs against Babesia gibsoni (Aomori strain).

Authors:  Aya Matsuu; Masahiro Yamasaki; Xuenan Xuan; Hiromi Ikadai; Yoshiaki Hikasa
Journal:  Vet Parasitol       Date:  2008-07-26       Impact factor: 2.738

Review 10.  Artemisinins: their growing importance in medicine.

Authors:  Sanjeev Krishna; Leyla Bustamante; Richard K Haynes; Henry M Staines
Journal:  Trends Pharmacol Sci       Date:  2008-08-25       Impact factor: 14.819

View more
  3 in total

1.  First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity.

Authors:  Shirin Bruderer; Noémie Hurst; Ruben de Kanter; Tommaso Miraval; Thomas Pfeifer; Yves Donazzolo; Jasper Dingemanse
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

2.  Activation of artemisinin and heme degradation in Leishmania tarentolae promastigotes: A possible link.

Authors:  Gerald Geroldinger; Matthias Tonner; Judith Quirgst; Martin Walter; Sritama De Sarkar; Laura Machín; Lianet Monzote; Klaus Stolze; J Catharina Duvigneau; Katrin Staniek; Mitali Chatterjee; Lars Gille
Journal:  Biochem Pharmacol       Date:  2019-11-29       Impact factor: 5.858

Review 3.  The global pipeline of new medicines for the control and elimination of malaria.

Authors:  Melinda P Anthony; Jeremy N Burrows; Stephan Duparc; Joerg J Moehrle; Timothy N C Wells
Journal:  Malar J       Date:  2012-09-07       Impact factor: 2.979

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.